Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win

Braveheart Bio announced a significant milestone as its cardiac drug, licensed from Jiangsu Hengrui Pharmaceuticals, achieved success in a mid-stage clinical trial. This development follows a recent win by Cytokinetics for a similar condition, highlighting the competitive landscape in heart muscle therapies.